Theratechnologies Inc (TH) to Post FY2018 Earnings of $0.13 Per Share, National Bank Financial Forecasts

Theratechnologies Inc (TSE:TH) – Investment analysts at National Bank Financial dropped their FY2018 earnings per share (EPS) estimates for shares of Theratechnologies in a research report issued to clients and investors on Wednesday. National Bank Financial analyst E. Leno now expects that the company will earn $0.13 per share for the year, down from their prior estimate of $0.14. National Bank Financial currently has a “Outperform” rating and a $8.75 price objective on the stock.

Theratechnologies (TH) traded down C$0.12 during trading on Friday, hitting C$7.04. 45,747 shares of the stock traded hands, compared to its average volume of 94,852. Theratechnologies has a 52 week low of C$3.41 and a 52 week high of C$8.72. The firm has a market capitalization of $536.84, a price-to-earnings ratio of -37.68 and a beta of 0.35.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/02/09/theratechnologies-inc-th-to-post-fy2018-earnings-of-0-13-per-share-national-bank-financial-forecasts.html.

About Theratechnologies

Theratechnologies Inc is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply